We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.89%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
+$361M
Cap. Flow
+$95.2M
Cap. Flow %
6.35%
Top 10 Hldgs %
63.32%
Holding
74
New
17
Increased
21
Reduced
30
Closed
4

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$33M
2
RVTY icon
Revvity
RVTY
+$31.9M
3
PFE icon
Pfizer
PFE
+$30.6M
4
VTRS icon
Viatris
VTRS
+$15.9M
5
INSP icon
Inspire Medical Systems
INSP
+$13.6M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$35.6M
2
IMGN
Immunogen Inc
IMGN
+$22.2M
3
ARGX icon
argenx
ARGX
+$12.1M
4
ILMN icon
Illumina
ILMN
+$12.1M
5
KRYS icon
Krystal Biotech
KRYS
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 89.26%
2 Miscellaneous 10.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNKD icon
26
MannKind Corp
MNKD
$1.27B
$10.8M 0.72%
+2,391,128
New +$9.39M
DHR icon
27
Danaher
DHR
$152B
$10.2M 0.68%
40,855
-186
-0.5% -$45.4K
LLY icon
28
Eli Lilly
LLY
$1.05T
$10M 0.67%
+12,877
New +$9.16M
ZIMV
29
DELISTED
ZimVie
ZIMV
$9.31M 0.62%
564,498
+18,054
+3% +$322K
GH icon
30
Guardant Health
GH
$21.7B
$9.27M 0.62%
+449,586
New +$9.64M
BKD icon
31
Brookdale Senior Living
BKD
$2.8B
$8.72M 0.58%
+1,318,765
New +$7.69M
NAMS icon
32
NewAmsterdam Pharma
NAMS
$3.1B
$8.37M 0.56%
353,965
-20,439
-5% -$415K
IMVT icon
33
Immunovant
IMVT
$8.51B
$8.26M 0.55%
255,526
+141,733
+125% +$5.17M
NVO
34
Novo Nordisk
NVO
$202B
$8M 0.53%
+62,344
New +$7.42M
KPTI icon
35
Karyopharm Therapeutics
KPTI
$42.4M
$7.57M 0.51%
+334,421
New +$5.86M
PBYI icon
36
Puma Biotechnology
PBYI
$468M
$7.56M 0.5%
1,426,497
-268,524
-16% -$1.45M
ELV icon
37
Elevance Health
ELV
$85.5B
$7.46M 0.5%
14,393
-701
-5% -$349K
TVTX icon
38
Travere Therapeutics
TVTX
$6.19B
$7.37M 0.49%
+955,618
New +$8.06M
CNC icon
39
Centene
CNC
$32B
$7.28M 0.49%
92,786
-4,412
-5% -$341K
BCRX icon
40
BioCryst Pharmaceuticals
BCRX
$2.51B
$7.28M 0.49%
1,432,427
-96,620
-6% -$543K
GOSS icon
41
Gossamer Bio
GOSS
$83.2M
$7.07M 0.47%
5,994,472
-438,243
-7% -$482K
TSHA icon
42
Taysha Gene Therapies
TSHA
$1.88B
$6.67M 0.45%
2,325,591
-1,455,123
-38% -$3.03M
TSVT
43
DELISTED
2seventy bio
TSVT
$6.3M 0.42%
1,177,678
+38,567
+3% +$181K
STRO icon
44
Sutro Biopharma
STRO
$339M
$6.17M 0.41%
109,142
+3,496
+3% +$154K
LQDA icon
45
Liquidia Corp
LQDA
$6.06B
$5.84M 0.39%
396,187
-292,739
-42% -$4.07M
NVRO
46
DELISTED
NEVRO CORP.
NVRO
$5.63M 0.38%
+389,663
New +$6.44M
AMRN
47
Amarin Corp
AMRN
$295M
$5.53M 0.37%
310,637
+5,862
+2% +$125K
MRUS
48
DELISTED
Merus
MRUS
$5.38M 0.36%
119,482
+3,756
+3% +$152K
ICLR icon
49
Icon
ICLR
$13.1B
$5.16M 0.34%
15,347
-70
-0.5% -$20.6K
WAT icon
50
Waters Corp
WAT
$40.7B
$4.69M 0.31%
13,628
-14,091
-51% -$4.63M
1
2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Eversept Partners held 74 positions worth $1.5B, up 32% from $1.14B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners deployed $95.2M of net new capital in Q1 2024, opening 17 new positions and adding to 21 existing holdings. Its largest new stake was Pfizer: 1,102,042 shares worth $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Natera, an estimated $35.6M trimmed.

  • Eversept Partners's largest Q1 2024 buy was Pfizer: 1,102,042 shares worth $30.6M.
  • Eversept Partners added most to GSK in Q1 2024, an estimated $33M increase.
  • Eversept Partners's biggest Q1 2024 reduction was Natera, cutting an estimated $35.6M.
  • Eversept Partners fully exited Immunogen Inc in Q1 2024, selling an estimated $22.2M.
  • Eversept Partners's ten largest holdings make up 63% of its $1.5B portfolio in Q1 2024.
  • Eversept Partners opened 17 new positions and closed 4 in Q1 2024.
  • Eversept Partners's portfolio value rose 32% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q1 2024, filed 15 May 2024.